The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors
Byron, Sara A., Chen, Huaibin, Wortmann, Andreas, Loch, David, Gartside, Michael G., Dehkhoda, Farhad, Blais, Steven P., Neubert, Thomas A., Mohammadi, Moosa and Pollock, Pamela M. (2013). The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. NeoPlasia, 15 (8), 975-988. doi: 10.1593/neo.121106